menu
    • menu
    [{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amifampridine","moa":"Potassium channel","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Dydo Pharma

    Menu

    Dydo Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dydo Pharma

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Dydo Pharma

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Catalyst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

                            Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that is indicated to treat Lambert-Eaton myasthenic syndrome.

                            Product Name : Firdapse

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Catalyst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dydo Pharma

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Dydo Pharma

                            Japan arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amifampridine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Catalyst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Catalyst Pharma Sub-Licensee Gets Approval For FIRDAPSE® in Japan

                            Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that received approval to treat Lambert-Eaton myasthenic syndrome in Japan.

                            Product Name : Firdapse

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 24, 2024

                            Lead Product(s) : Amifampridine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Catalyst Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth